Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients

The use of dipeptidyl peptidase 4 (DPP4) inhibitors, (also known as gliptins), is associated with an increased risk of bullous pemphigoid (BP), an autoimmune blistering skin disease. To explore the mechanism behind gliptin-associated BP we investigated circulating autoantibodies against the major BP...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Antti Nätynki, Päivi Leisti, Jussi Tuusa, Outi Varpuluoma, Laura Huilaja, Kentaro Izumi, Sanna-Kaisa Herukka, Olavi Ukkola, Juhani Junttila, Nina Kokkonen, Kaisa Tasanen
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	Frontiers Media S.A. 2022-07-01
श्रृंखला:	Frontiers in Immunology
विषय:	bullous pemphigoid autoimmunity BP180 gliptins DPP4 SDF-1 (CXCL12)
ऑनलाइन पहुंच:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.942131/full
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!